272 related articles for article (PubMed ID: 26778346)
1. Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration: A Discrete Choice Experiment.
Mueller S; Agostini H; Ehlken C; Bauer-Steinhusen U; Hasanbasic Z; Wilke T
Ophthalmology; 2016 Apr; 123(4):876-83. PubMed ID: 26778346
[TBL] [Abstract][Full Text] [Related]
2. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
[TBL] [Abstract][Full Text] [Related]
3. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
4. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
Arnold JJ; Campain A; Barthelmes D; Simpson JM; Guymer RH; Hunyor AP; McAllister IL; Essex RW; Morlet N; Gillies MC;
Ophthalmology; 2015 Jun; 122(6):1212-9. PubMed ID: 25846847
[TBL] [Abstract][Full Text] [Related]
5. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM
Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317
[TBL] [Abstract][Full Text] [Related]
6. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
7. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.
Yonekawa Y; Andreoli C; Miller JB; Loewenstein JI; Sobrin L; Eliott D; Vavvas DG; Miller JW; Kim IK
Am J Ophthalmol; 2013 Jul; 156(1):29-35.e2. PubMed ID: 23668679
[TBL] [Abstract][Full Text] [Related]
8. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
[TBL] [Abstract][Full Text] [Related]
9. Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial.
Jaffe GJ; Ciulla TA; Ciardella AP; Devin F; Dugel PU; Eandi CM; Masonson H; Monés J; Pearlman JA; Quaranta-El Maftouhi M; Ricci F; Westby K; Patel SC
Ophthalmology; 2017 Feb; 124(2):224-234. PubMed ID: 28029445
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes.
Chang AA; Broadhead GK; Hong T; Joachim N; Syed A; Schlub TE; Toth L; Peto T; Zhu M
Ophthalmic Res; 2015; 55(2):84-90. PubMed ID: 26637166
[TBL] [Abstract][Full Text] [Related]
11. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).
Houston SK; Rayess N; Cohen MN; Ho AC; Regillo CD
Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596
[TBL] [Abstract][Full Text] [Related]
12. EPIRETINAL MEMBRANES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy.
Karaca EE; Kepez Yldz B; Çubuk MÖ; Özdek Ş
Retina; 2015 Aug; 35(8):1540-6. PubMed ID: 25768251
[TBL] [Abstract][Full Text] [Related]
13. Treatment of age-related neovascular macular degeneration: the patient's perspective.
Müller S; Ehlken C; Bauer-Steinhusen U; Lechtenfeld W; Hasanbasic Z; Agostini H; Wilke T
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2237-2246. PubMed ID: 28776095
[TBL] [Abstract][Full Text] [Related]
14. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
Fauser S; Viebahn U; Muether PS
Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
[TBL] [Abstract][Full Text] [Related]
15. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
[TBL] [Abstract][Full Text] [Related]
16. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
Lee H; Ji B; Chung H; Kim HC
Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
[TBL] [Abstract][Full Text] [Related]
17. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
18. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
[TBL] [Abstract][Full Text] [Related]
19. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.
Homer N; Grewal DS; Mirza RG; Lyon AT; Gill MK
Eye (Lond); 2015 Sep; 29(9):1152-5. PubMed ID: 26021870
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting.
Boulanger-Scemama E; Querques G; About F; Puche N; Srour M; Mane V; Massamba N; Canoui-Poitrine F; Souied EH
J Fr Ophtalmol; 2015 Sep; 38(7):620-7. PubMed ID: 25913443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]